Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:protein
gptkb:enzyme |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2003 |
| gptkbp:ATCCode |
A16AB05
|
| gptkbp:brand |
gptkb:Aldurazyme
|
| gptkbp:CASNumber |
112648-35-2
|
| gptkbp:developedBy |
gptkb:BioMarin_Pharmaceutical
gptkb:Genzyme |
| gptkbp:drugClass |
enzyme replacement therapy
|
| https://www.w3.org/2000/01/rdf-schema#label |
laronidase
|
| gptkbp:indication |
gptkb:Hurler-Scheie_syndrome
gptkb:Hurler_syndrome gptkb:Scheie_syndrome |
| gptkbp:mechanismOfAction |
replaces alpha-L-iduronidase enzyme
|
| gptkbp:molecularWeight |
83 kDa
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fever
nausea abdominal pain headache chest pain rash allergic reactions breathing difficulties |
| gptkbp:target |
mucopolysaccharidosis type I
|
| gptkbp:UNII |
QY8P1J783E
|
| gptkbp:usedFor |
treatment of mucopolysaccharidosis I
|
| gptkbp:bfsParent |
gptkb:alpha-L-iduronidase
|
| gptkbp:bfsLayer |
6
|